Newcomers will not only be plugging into UPS while its forward-looking yield stands at 7.4%, but while the stock's priced ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...